Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash & Equivalents (2016 - 2025)

Viking Therapeutics' Cash & Equivalents history spans 12 years, with the latest figure at $165.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 521.57% year-over-year to $165.8 million; the TTM value through Dec 2025 reached $165.8 million, up 521.57%, while the annual FY2025 figure was $165.8 million, 521.57% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $165.8 million at Viking Therapeutics, up from $100.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $195.6 million in Q1 2024 and bottomed at $8.8 million in Q2 2021.
  • The 5-year median for Cash & Equivalents is $36.9 million (2022), against an average of $56.5 million.
  • The largest annual shift saw Cash & Equivalents surged 1629.43% in 2022 before it tumbled 80.6% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $26.4 million in 2021, then skyrocketed by 38.91% to $36.6 million in 2022, then soared by 51.55% to $55.5 million in 2023, then crashed by 51.95% to $26.7 million in 2024, then skyrocketed by 521.57% to $165.8 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Cash & Equivalents are $165.8 million (Q4 2025), $100.4 million (Q3 2025), and $33.9 million (Q2 2025).